Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522170 · ClinicalTrials.gov registry record
aHUS Observational Long Term Follow-Up
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- 94
- Enrollment target
NCT01522170: Clinical Trial study, sponsored by Alexion Pharmaceuticals.
NCT01522170 is a clinical trial that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 94 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01522170 was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- 94 participants
- Enrollment target
Study Summary
There is growing but limited information on the long term clinical status of aHUS patients who have previously received or are continuing to receive treatment with eculizumab. This study is designed to collect clinical data that will provide insight into the long-term outcomes of patients with aHUS.
Primary Outcome
Assess the long term efficacy of eculizumab in patients with aHUS who have previously participated in an eculizumab clinical study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2012-03 |
| Est. Completion | 2017-01 |
Why NCT01522170 stopped before completion
NCT01522170 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 94 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01522170 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01522170 about?
NCT01522170 is a clinical study titled "aHUS Observational Long Term Follow-Up". There is growing but limited information on the long term clinical status of aHUS patients who have previously received or are continuing to receive treatment with eculizumab. This study is designed to collect clinical data that will provide insight into the long-term outcomes of patients with aHUS.
What is the current status of trial NCT01522170?
This trial is currently terminated. The enrollment target is 94 participants. The study started on 2012-03. Estimated completion is 2017-01.
Who is sponsoring clinical trial NCT01522170?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia